| Title: | Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : an observational study |
|---|
| Authors: | ID Hochmair, Maximilian J (Author)
ID Morabito, Alessandro (Author)
ID Hao, Desiree (Author)
ID Yang, Cheng-Ta (Author)
ID Soo, Ross A (Author)
ID Yang, James C-H (Author)
ID Gucalp, Rasim (Author)
ID Halmos, Balazs (Author)
ID Wang, Lara (Author)
ID Golembesky, Amanda (Author)
ID Märten, Angela (Author)
ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Author) |
|---|
| Files: |  PDF - Presentation file, download (2,39 MB)
MD5: 3F2D8BA9D4F2488B02256DB856ABFA69
 URL - Source URL, visit https://www.futuremedicine.com/doi/full/10.2217/fon-2018-0711?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed#
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
|
|---|
| Abstract: | Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment [>/=]10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. |
|---|
| Keywords: | lung neoplasms -- therapy, non-small-cell lung cancer, afatinib, osimertinib, epidermal growth factor receptor, EGFR, observational study |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Place of publishing: | Velika Britanija |
|---|
| Publisher: | Future Medicine Ltd |
|---|
| Year of publishing: | 2018 |
|---|
| Number of pages: | str. 2861-2874 |
|---|
| Numbering: | Vol. 14, no. 27 |
|---|
| PID: | 20.500.12556/DiRROS-12623  |
|---|
| UDC: | 616-006 |
|---|
| ISSN on article: | 1744-8301 |
|---|
| DOI: | 10.2217/fon-2018-0711 |
|---|
| COBISS.SI-ID: | 2048432753 |
|---|
| Copyright: | 2018 Maximilian Hochmair |
|---|
| Note: | Soavtorji: Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten & Tanja Cufer;
Nasl. z nasl. zaslona;
Opis vira z dne 9. 1. 2019;
|
|---|
| Publication date in DiRROS: | 09.11.2020 |
|---|
| Views: | 1880 |
|---|
| Downloads: | 1090 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
